Effect of self-designedFuzheng-Quxie-Jiedu decoction combined with chemotherapy on breast cancer

Shucai XU

ABSTRACT

ObjectiveTo study the effect of self-designedFuzheng-Quxie-Jiedu decoction on transferring, relapse and liver quality of breast cancer patients after operation.Methods144 breast cancer patients after operation were divided into a study group and a control group. The control group was treated with CTF chemotherapy, and the study group was additionally treated with Chinese medicine. Both groups were treated for for 6 months. The 5-year recurrent rate and TCM syndrome scoring of the two groups were compared. The QOL was evaluated by SF-36 scale, and the related risk factors were tested by Logistic analysis. ResultsAfter treatment, the 5-year transferring recurrent rate of the study group lower than the control group (11.63%vs. 25.86%,χ2=4.892,P=4.892). The SF-36 scale body condition (72.11 ± 10.41 vs. 64.59 ± 9.83, t=3.252), social function (65.61 ± 12.54 vs. 58.94 ± 11.62,t=3.302), body role function (55.84 ± 10.65 vs. 47.46 ± 9.18,t=3.487), body pain (66.62 ± 12.53 vs. 60.68 ± 11.76,t=2.859), mental health (67.64 ± 11.35 vs. 62.65 ± 12.10,t=3.449), emotional role function (60.44 ± 9.20 vs. 55.04 ± 9.44),t=2.624), (69.77 ± 9.43 vs. 62.47 ± 10.12,t=3.557), and general health status (68.46 ± 10.25 vs. 62.45 ± 11.78,t=3.216) in the study group were all significantly increased comparing with the control group (P < 0.05). Results of logistic regression analysis showed that the transferring risk factors for recurrence were TNM staging (OR=1.984, 95%CI 1.510-2.607) and tumor size (OR=2.015, 95% CI2.015-2.847), the number of axillary lymph nodes (+) (OR=2.114, 95%CI 2.114-2.759), Chinese medicine adjuvant chemotherapy (OR=0.389, 95% CI0.235-0.644) and CD4/CD8 (OR=0.487, 95%CI 0.487-0.748).ConclusionSelf-designedFuzheng-Quxie-Jiedu decoction combined with standard chemotherapy can obviously reduce the recurrent rate of the postoperative patients with breast cancer, improve the quality of life and improve the clinical symptoms.